The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange (NYSE) in New York. (Reuters)
- Youth hardest hit by COVID-19 Read More
- Branding key to selling Bajan and Caribbean products, says Caddle Read More
- ECB wants substitute rule for coronavirus Read More
- Hill open to motoring restrictions Read More
- Wanted: A more efficient airport Read More
- Low-hanging fruit for all Read More
- Avatar sequel to resume filming in New Zealand Read More
BENGALURU/LONDON – The United States has secured almost a third of the first one billion doses planned for AstraZeneca’s experimental COVID-19 vaccine by pledging up to US$1.2 billion, as world powers scramble for medicines to get their economies back to work.
While not yet proven to be effective against the coronavirus, vaccines are seen by world leaders as the only real way to restart their stalled economies, and even to get an edge over global competitors.
After United States President Donald Trump demanded a vaccine, the US Department of Health and Human Services (HHS) agreed to provide up to US$1.2 billion to accelerate British drugmaker AstraZeneca’s (AZN.L) vaccine development and secure 300 million doses for the United States.
“This contract with AstraZeneca is a major milestone in Operation Warp Speed’s work toward a safe, effective, widely available vaccine by 2021,” US Health Secretary Alex Azar said. The first doses could be available in the United States as early as October, according to a statement from HHS.
The vaccine, previously known as ChAdOx1 nCoV-19 and now as AZD1222, was developed by the University of Oxford and licensed to AstraZeneca. Immunity to the new coronavirus is uncertain and so the use of vaccines is unclear.
The US deal allows a late-stage, or Phase III, clinical trial of the vaccine with 30 000 people in the United States.
Cambridge, England-based AstraZeneca said it had concluded agreements for at least 400 million doses of the vaccine and secured manufacturing capacity for one billion doses, with first deliveries due to begin in September.
Now the most valuable company on Britain’s blue-chip FTSE 100 Index, AstraZeneca has already agreed to deliver 100 million doses to people in Britain, with 30 million as soon as September. Ministers have promised Britain will get first access to the vaccine. (Reuters)